Robert J Weiss

Summary

Affiliation: Androscoggin Cardiology Associates
Country: USA

Publications

  1. doi Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, Maine 04210 5967, USA
    Clin Ther 33:1150-61. 2011
  2. ncbi Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 8:706-12. 2006
  3. ncbi Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, Maine 04210, USA
    Clin Ther 24:1451-62. 2002
  4. ncbi Nebivolol: novel beta-blocker with nitric oxide-induced vasodilation
    Robert Weiss
    Androscoggin Cardiology Research, 2 Great Falls Plaza, Auburn, ME 04210, USA
    Future Cardiol 2:9-16. 2006
  5. ncbi A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 9:667-76. 2007
  6. ncbi The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, ME 14210, USA
    Clin Ther 25:1490-7. 2003
  7. pmc Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation
    Robert Weiss
    Androscoggin Cardiology Associates, 2 Great Falls Plaza Auburn, ME 04210, USA
    Vasc Health Risk Manag 2:303-8. 2006
  8. doi Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial
    Robert J Weiss
    Maine Research Associates, 2 Great Falls Plaza, Auburn, ME 04210, USA
    Am J Cardiovasc Drugs 13:129-40. 2013
  9. ncbi Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris
    Carl J Pepine
    University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Am J Cardiol 91:274-9. 2003
  10. ncbi Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    William C Cushman
    J Clin Hypertens (Greenwich) 4:393-404. 2002

Detail Information

Publications14

  1. doi Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, Maine 04210 5967, USA
    Clin Ther 33:1150-61. 2011
    ..Nebivolol is a β(1)-selective β-blocker with NO-mediated vasodilatory properties, approved in the United States for the treatment of stage I-II hypertension...
  2. ncbi Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 8:706-12. 2006
    ..There appears to have been limited impact from the guidelines on initial drug choice and even less so on ongoing drug therapy...
  3. ncbi Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, Maine 04210, USA
    Clin Ther 24:1451-62. 2002
    ..The US Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure recommended beta-blockers and thiazide diuretics as the drugs of first choice for the initial treatment of hypertension...
  4. ncbi Nebivolol: novel beta-blocker with nitric oxide-induced vasodilation
    Robert Weiss
    Androscoggin Cardiology Research, 2 Great Falls Plaza, Auburn, ME 04210, USA
    Future Cardiol 2:9-16. 2006
    ..Nebviolol has been tested successfully in double-blind, placebo-controlled trials in both hypertension and congestive heart failure...
  5. ncbi A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 9:667-76. 2007
    ..002). The overall adverse event experience was similar in the nebivolol (46.1%) and placebo (40.7%) groups (P=.273). Once-daily nebivolol is an effective antihypertensive in mild to moderate hypertensive patients...
  6. ncbi The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
    Robert Weiss
    Androscoggin Cardiology Associates, Auburn, ME 14210, USA
    Clin Ther 25:1490-7. 2003
    ..Evidence shows that testing in the nonfasting state may not be clinically or significantly different from testing in the fasting state in identifying patients at risk for a future cardiovascular event...
  7. pmc Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation
    Robert Weiss
    Androscoggin Cardiology Associates, 2 Great Falls Plaza Auburn, ME 04210, USA
    Vasc Health Risk Manag 2:303-8. 2006
    ..This article will review published clinical data regarding this cardioselective beta-blocker...
  8. doi Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial
    Robert J Weiss
    Maine Research Associates, 2 Great Falls Plaza, Auburn, ME 04210, USA
    Am J Cardiovasc Drugs 13:129-40. 2013
    ..Most patients with hypertension require more than one antihypertensive to achieve blood pressure (BP) control...
  9. ncbi Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris
    Carl J Pepine
    University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Am J Cardiol 91:274-9. 2003
    ..Thus, nisoldipine-ER and amlodipine provided comparable antihypertensive and anti-ischemic efficacy, and both were generally well tolerated...
  10. ncbi Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    William C Cushman
    J Clin Hypertens (Greenwich) 4:393-404. 2002
    ..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
  11. ncbi Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
    Myron H Weinberger
    Indiana University School of Medicine, Hypertension Research Center, Indianapolis 46202 5111, USA
    Am J Hypertens 15:709-16. 2002
    ..Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension...
  12. ncbi Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial
    Ralph M Vicari
    MIMA Century Research Associates, Melbourne, Florida 32901, USA
    J Am Coll Cardiol 46:1803-11. 2005
    ..This study sought to evaluate the efficacy and safety of fasudil, an orally available rho kinase inhibitor, in patients with stable angina...
  13. ncbi Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease
    Paul Michael Grossman
    University of Michigan Healthcare System, Ann Arbor, MI 48109 0311, USA
    Am Heart J 153:874-80. 2007
    ....
  14. ncbi Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels
    David M Capuzzi
    Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Am J Cardiol 91:1304-10. 2003
    ..Similar increases in HDL cholesterol and apolipoprotein A-I were noted between the monotherapy groups. Over 24 weeks, rosuvastatin alone was better tolerated than either ER niacin alone or the combinations of rosuvastatin and ER niacin...